Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $47,612 | 2 | 99.2% |
| Food and Beverage | $406.01 | 10 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lumenis BE LTD | $47,612 | 2 | $0 (2024) |
| ABBVIE INC. | $167.58 | 3 | $0 (2024) |
| Allergan Inc. | $124.90 | 1 | $0 (2017) |
| EPI Health, LLC | $62.55 | 3 | $0 (2022) |
| Dermavant Sciences, Inc. | $20.40 | 1 | $0 (2024) |
| Lilly USA, LLC | $18.86 | 1 | $0 (2019) |
| STRATA Skin Sciences, Inc. | $11.72 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,588 | 5 | Lumenis BE LTD ($3,400) |
| 2023 | $44,212 | 1 | Lumenis BE LTD ($44,212) |
| 2022 | $62.55 | 3 | EPI Health, LLC ($62.55) |
| 2019 | $30.58 | 2 | Lilly USA, LLC ($18.86) |
| 2017 | $124.90 | 1 | Allergan Inc. ($124.90) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: DERMATOLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $12.68 | General |
| 10/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $4.90 | General |
| 06/12/2024 | Lumenis BE LTD | — | Honoraria | Cash or cash equivalent | $3,400.00 | General |
| 05/16/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 06/12/2023 | Lumenis BE LTD | — | Honoraria | Cash or cash equivalent | $44,212.00 | General |
| 12/20/2022 | EPI Health, LLC | CLODERM (Drug), MINOLIRA EXTENDED RELEASE, WYNZORA | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: DERMATOLOGY | ||||||
| 10/27/2022 | EPI Health, LLC | CLODERM (Drug), MINOLIRA EXTENDED RELEASE, WYNZORA | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: DERMATOLOGY | ||||||
| 09/22/2022 | EPI Health, LLC | CLODERM (Drug), MINOLIRA EXTENDED RELEASE, WYNZORA | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: DERMATOLOGY | ||||||
| 10/07/2019 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: Immunology | ||||||
| 03/28/2019 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $11.72 | General |
| Category: Dermatology | ||||||
| 02/28/2017 | Allergan Inc. | KYBELLA (Biological) | Food and Beverage | In-kind items and services | $124.90 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 283 | 510 | $81,610 | $26,266 |
| 2022 | 7 | 304 | 471 | $80,595 | $26,401 |
| 2021 | 6 | 334 | 541 | $104,460 | $34,303 |
| 2020 | 7 | 384 | 571 | $108,695 | $30,551 |
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 81 | 122 | $26,081 | $8,930 | 34.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 68 | 101 | $25,064 | $8,316 | 33.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 35 | 75 | $9,197 | $3,400 | 37.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 39 | 76 | $12,360 | $3,035 | 24.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 39 | 57 | $7,649 | $2,119 | 27.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 21 | 79 | $1,260 | $465.49 | 36.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 96 | 143 | $30,815 | $10,768 | 34.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 75 | 90 | $24,008 | $7,800 | 32.5% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 42 | 68 | $9,861 | $3,323 | 33.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 32 | 51 | $8,830 | $2,505 | 28.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 33 | 41 | $5,823 | $1,634 | 28.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 15 | 57 | $1,073 | $357.13 | 33.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 11 | 21 | $184.60 | $14.72 | 8.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 114 | 178 | $35,600 | $14,053 | 39.5% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 83 | 111 | $33,300 | $10,702 | 32.1% |
| 17000 | Destruction of skin growth | Office | 2021 | 42 | 72 | $14,400 | $3,757 | 26.1% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 47 | 68 | $13,600 | $3,631 | 26.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 26 | 35 | $5,250 | $1,669 | 31.8% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 22 | 77 | $2,310 | $491.37 | 21.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 124 | 195 | $39,000 | $11,690 | 30.0% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 89 | 105 | $31,500 | $9,374 | 29.8% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2020 | 46 | 82 | $16,400 | $4,359 | 26.6% |
| 17000 | Destruction of skin growth | Office | 2020 | 56 | 72 | $14,400 | $3,419 | 23.7% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 32 | 33 | $4,950 | $1,292 | 26.1% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 26 | 69 | $2,070 | $402.27 | 19.4% |
About Dr. Marc Avram, MD
Dr. Marc Avram, MD is a Specialist healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1629063748.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marc Avram, MD has received a total of $48,018 in payments from pharmaceutical and medical device companies, with $3,588 received in 2024. These payments were reported across 12 transactions from 7 companies. The most common payment nature is "Honoraria" ($47,612).
As a Medicare-enrolled provider, Avram has provided services to 1,305 Medicare beneficiaries, totaling 2,093 services with total Medicare billing of $117,522. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Practice Information
- Specialty Specialist
- Location Brooklyn, NY
- Active Since 09/14/2005
- Last Updated 11/10/2008
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1629063748
Products in Payments
- KYBELLA (Biological) $124.90
- CLODERM (Drug) $62.55
- VTAMA (Drug) $20.40
- TALTZ (Drug) $18.86
- XTRAC (Device) $11.72
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Brooklyn
Idan Sharon, M.d, M.D
Specialist — Payments: $2.3M
Dr. Sean Studer, M.d, M.D
Specialist — Payments: $411,591
Dr. Michael Lewis, M.d, M.D
Specialist — Payments: $68,268
Michael Amoashiy, Md, MD
Specialist — Payments: $41,408
Dr. Madhavi Reddy, M.d, M.D
Specialist — Payments: $40,649
Mr. Benjamin Wu
Specialist — Payments: $23,392